MRL Reference Laboratory
10703 Progress Way                                                                                                                  9600 Walker Street, #34
Cypress, CA  90630                                                                                                                   Cypress, CA  90630
(714) 220-1900 x250                                                                                                                  (714) 236-0355

CURRENT POSITION

January 1998 - Present Associate Director of Molecular Diagnostics

• Responsibilities include:

• Directing Molecular Based Laboratory for Esoteric Infectious Agents utilizing PCR, RFLP, Sequencing, Hybrid Capture and other molecular technologies
• Developing and Validating New Medical Diagnostic Tests and/or Technologies
• Improving Assay Formats with regard to sensitivity and specificity
• Developing and Validating New Medical Diagnostic Tests and/or Technologies
• Improving Assay Formats with regard to sensitivity and specificity
• Providing Technical Leadership in the Area of Clinical Molecular Tests
• Disseminating Molecular Technologies to other MRL Laboratorie

January 1994 - January 1998 Director of Research and Development
 Pel-Freez Molecular Diagnostics, Rogers, AR
Responsibilities included:
•  Directing Research and Development Activities
•  Overseeing a multimillion dollar Fermentation and Bioprocessing Facility
•  Developing novel and unique reagents for Medical Diagnostic Tests
•  Developing recombinant based products to replace native enzymes and proteins
•  Matrix manager of several intercompany research projects
•  Providing technical input into current and new product manufacturing

October 1990 - December 1993 Director of New Products and Technical Services
 Pel-Freez Biologicals,  Rogers, AR
Responsibilities included:
•  Research and Development of new diagnostic reagents and products
•  Evaluating emerging technologies for possible purchase or licensing
•  Directing development of product improvements of existing products
•  Serving as the scientific liaison for custom projects between Pel-Freez and other companies, including our sister divisions, Pel-Freez Clinical Systems and Novagen
•  Managing the antisera production of a 63 acre farm facility
•  Overseeing and Updating Quality Control Laboratories
    •  Responsible for 5 direct reports and two department budgets

EDUCATION

1990 Positive Power and Influence,  Syntex Management Retreats, Palo Alto, CA
1989 Managing at Syntex Bootcamp, Syntex Management Retreats, Palo Alto, CA
1987 Essentials of Supervision,  Zenger/Miller Management Course
1986  Project Management, Univ. of California Graduate School, Berkeley, CA

1981 - 1983 Postdoctoral Associate
 with Dr. Richard G. Lynch, Department of Pathology
 University of Iowa College of Medicine, Iowa City, IA

1982 Clinical Immunology (Pathology Resident's Core Training)
 University of Iowa College of Medicine, Iowa City, IA

1979 - 1981 National Cancer Institute Postdoctoral Trainee
 with Dr. Richard G. Lynch, Department of Pathology
 Washington University School of Medicine, St. Louis, MO

July 1981 Histopathobiology of Cancer Course
 Sponsored by the National Cancer Institute, Keystone, CO

1974 - 1978 Ph.D. Microbiology and Immunology, Awarded January 1979
 Department of Microbiology
 University of Kansas, Lawrence, KS

1970 - 1974 B.G.S. Microbiology, (Minor:  Biochemistry)
 University of Kansas, Lawrence, KS

PAST RESEARCH and WORK EXPERIENCE

1990 - 1998 DEVELOP INNOVATIVE PRODUCTS AND APPLICATIONS
Pel-Freez Biologicals  Developed new products and product improvements within the core
and Molecular Diagnostics competencies and current product families of Pel-Freez.  Evaluate new technologies and Rogers, AR products for possible licensing.

1983 - 1990 NOVEL mAb TECHNIQUES AND ASSAY DEVELOPMENT
Research Department Developed unique and ultrasensitive immunoassays based on antibody
Syva Company  idiotype-anti-idiotype interactions.  Assay development in areas of infectious disease,
Palo Alto, CA therapeutic drug and drug of abuse diagnostics

 Developed novel strategies for the induction and production of human and murine monoclonal antibodies including:  i) B cell and T cell immunoregulation for the enhancement or suppression of appropriate lymphocyte clones;  ii) induction and selection of isotype switch variants and monoclonal antibodies with varied specificity,reactivity or effector function; and iii) In Vitro  immunization.

1981 - 1983 MOLECULAR AND CELLULAR MECHANISMS OF IMMUNOREGULATION
Univ. of Iowa Medical School Dissection of the precise molecular events (at the RNA level) associated
Iowa City, IA with the suppression of B cell antibody secretion by idiotype-specific T lymphocytes.  These studies led to a better understanding of normal B cell regulation as well as being instrumental in the development of immunotherapeutic strategies against malignant lymphocyte clones.

1979 - 1981 MONOCLONAL AND POLYCLONAL ANTI-IDIOTYPIC ANTIBODIES
Washington Univ. School Establishment of an in vitro  system for the immunoregulation of the
of Medicine murine myeloma, MOPC-315.  Isologous monoclonal and polyclonal anti-
St. Louis, MO idiotype antibodies were generated and tested for their effect on:  i) surface expression and secretion of the idiotype-bearing immunoglobulin of MOPC-315; and ii) direct cytotoxic or cytostatic effects on the myeloma cells.

1974 - 1979 Regulation of the anti-autologous erythrocyte immune
Univ. of Kansas response among normal rabbit gut-associated lymphoid
Lawrence, KS tissues in vitro and in vivo .  (Dissertation) Advisor:  Dr. Laurence R. Draper, Professor

RESEARCH EXPERTISE

New and Novel Infectious Disease Diagnostic Assays
 PCR and RT-PCR
 RFLP and Single Point Mutation Detection
 Plate Based and Gel-Based Nucleic Acid Detection
 DNA Sequencing
 Homogeneous and Heterogeneous Enzyme-linked Immunoassays
 Automated EIA and Disposable Single test Immunoassay Development in Infectious disease, Therapeutic drugs and Drugs of abuse Immunoassays
 Macro and Micro Bead, Magnetic Bead, Chemiluminescent Assays
 Hybridoma Technology (B and T Cell Fusions)
 Immunologic Manipulation  (isotype switching, neonatal suppression, affinity selection, antigen-specific B cell selection, in-vitro immunization, etc.)
 In Vitro  Antibody Production (ACUSYS-P, ACUSYS-JR, Cell-Pharm)
 Immunoglobulin Purification, Fragmentation, and Conjugation
 Affinity, Ion Exchange and Gel Filtration Chromatography
 Northern, Southern and Western Hybridizations
 Expression of Recombinant Proteins and Enzymes
 Direct and Indirect Fluorescence Microscopy

TEACHING EXPERIENCE

1974-1982 Medical, Graduate, Undergraduate and Medical Technology Students
 University of Iowa College of Medicine, Washington University School of Medicine, Southern Illinois University, University of Kansas
 Immunology and Microbiology Lectures
 Tumor Immunology and Idiotype Network Lectures, Microbiology Laboratory, Immunology Laboratory
 Microbial Pathogenics Laboratory

PUBLICATIONS

Lynch, R.G., Rohrer, J.W., Gebel, H. M., Odermatt, B.F., Hoover, R.G., Milburn, G. L. and Mordhorst, R.  (1980).  Antigen-binding myeloma cells:  Monoclonal models of B cell differentiation.  IN:  Progress in Myeloma , E. P. Cohen and H. Kohler, editors, Alan R. Liss, Inc., New York, New York, pp. 325-344.

Milburn, G. L. and Lynch, R.G. (1980).   Immunoregulation of the clonal expansion and differentiation of murine myeloma cells.  IN:  Proceedings of the International Workshop on Recent Advances and Future Trends in Myeloma.  Montpellier, France.  Academic Press, London, England, pp. 182-189.

Milburn, G. L. and Lynch, R .G. (1981).  Myeloma proteins are clone-specific markers whose expression can be regulated by the myeloma-bearing host.  Proceedings of the International Leukemia Marker Conference, Vienna, Austria.  IN:  Leukemia Markers.  W. Knapp, Editor, Academic Press, London, England, pp. 261-264.

Milburn, G. L., Hoover, R.G., Dieckegraefe, B. K. and Lynch, R.G. (1981).  Immunoregulatory cell interactions in myeloma:  Myeloma cells are targets and inducers of immunoregulatory cells.  Proceedings of 2nd International Symposia on  B Cells in the Immune Response, Scottsdale, Arizona.  IN:  B Lymphocytes in the Immune Response:  Functional, Developmental and Interactive Properties.  N. Klinman, D. Mosier, D. Scher and E. Vitetta, editors.  Elsevier North Holland, New York, New York  pp. 485-492.

Lynch, R.G., Milburn, G. L., Hoover, R.G., Rohrer, J.W. and Dieckegraefe, B.K.  (1981).  Myeloma proteins are targets and inducers of immunoregulatory signals.  IN:  Immunoglobulin Idiotypes.  C. Janeway, E. Sercarz, H. Wigzell and C. Fox, editors, Academic Press, New York, New York  pp. 595-611.

Milburn, G. L. and Lynch, R.G.  (1982).  "Immunoregulation of murine myeloma in vitro:  II.  Suppression of MOPC-315 immunoglobulin secretion and synthesis by idiotype-specific suppressor T cells."  J. Exp. Medicine 155:852-861.

Milburn, G. L., Hoover, R.G., and Lynch, R.G.  (1982).  Immunoregulatory cell interactions that govern the growth and differentiation of murine myeloma cells.  IN:  B and T Cell Tumors:  Biological and Clinical Aspects.  E.  Vitetta and C. Fox, editors.  Academic Press, New York, New York  pp. 335-348.

Milburn, G. L., Hoover, R.G., and Lynch, R.G.  (1982).  The use of myeloma cells to analyze immunoregulatory mechanisms and visualize immunoregulatory circuits.  IN:  Regulatory Immune Response Dynamics.  C. DeLisi and J. Hiernaux, editors, CRC Press, Inc., Boca Raton, Florida, pp. 141-155.

Milburn, G. L., and Lynch, R.G. (1983).  Anti-idiotypic regulation of IgA expression in myeloma cells.  Molecular Immunology  20:931-940.

Parslow, T.G., Milburn, G. L., Lynch, R.G. and Granner, D.K. (1983).  Suppressor T cell action inhibits the expression of an excluded immunoglobulin gene.  Science  220:1389-1391.

Lynch, R.G. and Milburn, G. L.  (1983).  The use of myeloma cells to study immunoregulatory mechanisms.  Immunology Today  4:326-329.

Milburn, G. L., Parslow, T.G., Goldenberg, C., Granner, D.K. and Lynch, R.G.  (1984).  Idiotype-specific T cell suppression of light chain mRNA expression in MOPC-315 cells is accompanied by a post-transcriptional inhibition of heavy chain expression.  J. Molec. and Cellular Immunology  1:115-123.

Lynch, R.G., Milburn, G. L. and Hoover, R.G.  (1984).  Cellular and molecular mechanisms regulate idiotype expression in myeloma cells.  New York Academy of Sciences.  IN:  Immune Networks .  C. Bona and H Kohler, editors.  Ann. N.Y. Acad. Sciences. 418:346-355.

Lynch, R.G. and Milburn, G. L.  (1984).  Murine plasmacytoma MOPC-315 as a tool for the analysis of network regulation:  M315 idiotypes are inducers and targets of immunoregulatory signals.  IN:  The Biology of Idiotypes .  M. Greene and A Nisonoff, editors.  Academic Press, New York, New York pp. 299-313.

Lynch, R.G. and Milburn, G. L.  (1984).  Cellular and molecular mechanisms that regulate immunoglobulin expression in myeloma cells.  IN:  Progress in Immunology V .  Academic Press Japan, Tokyo, Japan, V:719-726.

Lynch, R.G. and Milburn, G. L.  (1984).  Developmental stages of myeloma cells.  Transplantation Proceedings .  16:458-459.

Milburn, G. L. and Lynch, R.G.   Suppressor T cells specific for the M315 idiotype are directed to VH315 determinants.  (in preparation).

Ulman, E. F., Milburn, G. L., Jelesko, J., Radika, K., Pirio, M., Kempe, T., and Skold, C.   (1993).  Anti-immune complex antibodies enhance affinity and specificity of primary antibodies.  Proc. Natl. Acad. Sci. USA.  90:1184-1189.

Milburn, G. L., Carrigan, D., Dienglewicz, R., Kernan, N., Papadopolos, E., and Singh, N.   Diagnosis of Active Human Herpesvirus Six (HHV6) Infections in Immunocompromised Patients with a Rapid Shell-Viall Assay.  (1995)  ASM Abstract, New Orleans, LA..
 

PROFESSIONAL SOCIETIES

American Association of Immunologists,  elected 1984
 American Association of Pathologists,  elected 1983
 American Association of Microbiology
 American Association of Clinical Chemistry
 New York Academy of Sciences
 American Association for the Advancement of Science
 Phi Sigma,  elected 1981

REFERENCES

 Provided upon request.